Statistiche di base
| CIK | 1424768 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vycor Medical, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its ch |
|
| August 8, 2025 |
Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2025 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2025 BOCA RATON, FL (August 8, 2025) – Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2025 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2025 |
Vycor Medical Releases Financial Results for the Three Months Ended March 31, 2025 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three Months Ended March 31, 2025 BOCA RATON, FL (May 15, 2025) – Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB—VYCO), today announced financial results for the three months ended March 31, 2025. The company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurge |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its c |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. (Exac |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2025 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 15, 2025 |
Vycor Medical Releases Financial Results for the year ended December 31, 2024 Exhibit 99.1 Vycor Medical Releases Financial Results for the year ended December 31, 2024 BOCA RATON, FL (April 15, 2025) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the year ended December 31, 2024. The company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision®, whi |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-53754 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 11-K ☐ Form 20-F ☐ Form 10-Q ☐ Form N-SAR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its ch |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its c |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. (Exac |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-53754 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 11-K ☐ Form 20-F ☐ Form 10-Q ☐ Form N-SAR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its ch |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its c |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. (Exac |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-53754 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 11-K ☐ Form 20-F ☐ Form 10-Q ☐ Form N-SAR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| October 18, 2022 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Forty-Fourth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its ch |
|
| July 13, 2022 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Forty-Third Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Ma |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its c |
|
| April 13, 2022 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Forty-Second Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. (Exac |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-53754 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 11-K ? Form 20-F ? Form 10-Q ? Form N-SAR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR ? Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| January 18, 2022 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Forty-First Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Ma |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| October 8, 2021 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Fortieth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manag |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its ch |
|
| July 20, 2021 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Ninth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2021 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Eighth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. ( |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2021 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Seventh Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified |
|
| October 6, 2020 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Sixth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| August 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-53754 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| August 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in it |
|
| July 8, 2020 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Fifth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| June 30, 2020 |
Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement BOCA RATON, FL (June 30, 2020) – Vycor Medical, Inc. (“Vycor”) (OTCBB—VYCO) today announced that its wholly owned subsidiary, NovaVision, Inc. (“NovaVision”), has signed an agreement in principle to enter into an exclusive licensing agreement with HelferApp GmbH (“HelferApp”). Under the terms of the agr |
|
| June 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2020 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| April 7, 2020 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment SC 13D/A 1 sc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Fourth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) |
|
| March 27, 2020 |
VYCO / Vycor Medical, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. ( |
|
| March 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2020 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 27, 2020 |
Vycor Medical Reports Financial Results for the year ended December 31st, 2019 Vycor Medical Reports Financial Results for the year ended December 31st, 2019 BOCA RATON, FL (March 27, 2020) – Vycor Medical, Inc. |
|
| January 7, 2020 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Third Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| November 12, 2019 |
VYCO / Vycor Medical, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified |
|
| October 9, 2019 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-Second Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital |
|
| August 9, 2019 |
VYCO / Vycor Medical, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in it |
|
| July 2, 2019 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirty-First Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| May 13, 2019 |
VYCO / Vycor Medical, Inc. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| April 3, 2019 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirtieth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Mana |
|
| March 29, 2019 |
Vycor Medical Reports Financial Results for the year ended December 31st, 2018 Exhibit 99.1 Vycor Medical Reports Financial Results for the year ended December 31st, 2018 BOCA RATON, FL (March 29, 2018) – Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2018. Highlights ● Vycor has been working on improving how its VBAS integrates with the most commo |
|
| March 29, 2019 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2019 Vycor Medical, Inc. (Exact name of registrant) Delaware 001-34932 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identi |
|
| March 29, 2019 |
VYCO / Vycor Medical, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. ( |
|
| January 8, 2019 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Ninth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| November 13, 2018 |
VYCO / Vycor Medical, Inc. 10-Q (Quarterly Report) 10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business |
|
| October 23, 2018 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Eighth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital |
|
| October 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2018 Vycor Medical, Inc. (Exact name of registrant) Delaware 001-34932 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) |
|
| October 12, 2018 |
Letter to Securities and Exchange Commission from Paritz & Company, P.A., dated October 12, 2018 EX-16.1 2 ex16-1.htm Exhibit 16.1 October 12, 2018 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have read Item 4.01 of Form 8-K of Vycor Medical, Inc. dated October 9, 2018. We agree with the statements made concerning our firm contained therein. Yours very truly, /s/ Paritz & Company, P.A. Hackensack, New Jersey |
|
| August 10, 2018 |
VYCO / Vycor Medical, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in it |
|
| July 11, 2018 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Seventh Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital |
|
| May 11, 2018 |
VYCO / Vycor Medical, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| April 24, 2018 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Sixth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| March 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2018 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) |
|
| March 30, 2018 |
Vycor Medical Reports Financial Results for the year ended December 31st, 2017 Exhibit 99.1 Vycor Medical Reports Financial Results for the year ended December 31st, 2017 BOCA RATON, FL (March 30, 2018) – Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2017. Vycor’s revenues for the year ended December 31, 2017 were $1,385,000 compared to $1,452,000 |
|
| March 30, 2018 |
VYCO / Vycor Medical, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34932 VYCOR MEDICAL, INC. ( |
|
| March 13, 2018 |
VYCO / Vycor Medical, Inc. DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [X] Definitive Information Statement V |
|
| March 1, 2018 |
VYCO / Vycor Medical, Inc. 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C/A (RULE 14C-101) (Amendment No. 1) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [ ] Definitive Inf |
|
| February 12, 2018 |
VYCO / Vycor Medical, Inc. 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [ ] Definitive Information Statement V |
|
| February 12, 2018 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Fifth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| November 13, 2017 |
Vycor Medical Reports Financial Results for the three and nine months ended September 30th, 2017 Exhibit 99.1 Vycor Medical Reports Financial Results for the three and nine months ended September 30th, 2017 BOCA RATON, FL (November 13, 2017) ? Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the three and nine months ended September 30, 2017. Vycor?s revenues for the nine months ended September |
|
| November 13, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Numbe |
|
| November 13, 2017 |
VYCO / Vycor Medical, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2017 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified |
|
| September 15, 2017 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Fourth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital |
|
| September 15, 2017 |
VYCO / Vycor Medical, Inc. / ZACHARIOU PETER C Activist Investment SC 13D/A 1 sc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Fifth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRRED STOCK PAR VALUE $0.0001 (Title of Class of Securi |
|
| August 11, 2017 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2017 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Iden |
|
| August 11, 2017 |
Vycor Medical Reports Financial Results for the three and six months ended June 30th, 2017 Exhibit 99.1 Vycor Medical Reports Financial Results for the three and six months ended June 30th, 2017 BOCA RATON, FL (August 11, 2017) ? Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the three and six months ended June 30, 2017. Vycor?s revenues for the six months ended June 30, 2017 were $736,0 |
|
| August 11, 2017 |
VYCO / Vycor Medical, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2017 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in it |
|
| July 21, 2017 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Third Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| May 11, 2017 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identif |
|
| May 11, 2017 |
Vycor Medical Reports Financial Results for the Period ended March 31st, 2017 Exhibit 99.1 Vycor Medical Reports Financial Results for the Period ended March 31st, 2017 BOCA RATON, FL (May 11, 2017) ? Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the period ended March 31, 2017. Vycor?s revenues for the period ended March 31, 2017 were $428,000 compared to $400,000 for 2016 |
|
| May 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2017 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| April 11, 2017 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-Second Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital |
|
| April 6, 2017 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twenty-First Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital M |
|
| March 31, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2017 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) |
|
| March 31, 2017 |
Vycor Medical Reports Financial Results for the year ended December 31st, 2016 EX-99.1 2 ex99-1.htm Exhibit 99.1 Vycor Medical Reports Financial Results for the year ended December 31st, 2016 BOCA RATON, FL (March 31, 2017) – Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2016. Vycor’s revenues for the year ended December 31, 2016 were $1,452,000 c |
|
| March 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-149782 VYCOR MEDICAL, INC. |
|
| March 3, 2017 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twentieth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Mana |
|
| February 27, 2017 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2017 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of (Commission (I.R.S. Employer |
|
| January 20, 2017 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment SC 13D/A 1 sc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Nineteenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fo |
|
| January 13, 2017 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Eighteenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Man |
|
| January 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2017 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 14, 2016 |
Vycor Medical Reports Financial Results for the three and nine months ended September 30th, 2016 Exhibit 99.1 Vycor Medical Reports Financial Results for the three and nine months ended September 30th, 2016 BOCA RATON, FL (November 14, 2016) ? Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the three and nine months ended September 30, 2016. Vycor?s revenues for the quarter were $326,000 compar |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2016 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Numbe |
|
| November 14, 2016 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its ch |
|
| November 8, 2016 |
Vycor Medical /A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K First Amendment [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-149782 VYCO |
|
| November 8, 2016 |
Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 November 8, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Kevin J. Kuhar, Accounting Branch Chief Re: Vycor Medical, Inc. (the ?Company?) Form 10-K for the Fiscal Year Ended December 31, 2015 Filed March 30, 2016 Form 8-K dated August |
|
| October 21, 2016 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-196334 Dated October 14, 2016 VYCOR MEDICAL, INC. 3,991,202 Shares of Common Stock Par Value $0.0001 Per Share This prospectus relates to the offering by the selling stockholders of VYCOR MEDICAL, INC. of up to 3,991,202 shares of our common stock underlying Series A and Series B warrants, par value $0.0001 per share. We will not receive any pr |
|
| October 11, 2016 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Seventeenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Ma |
|
| October 5, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-196334 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave |
|
| October 5, 2016 |
Youâve Exceeded the SECâs Traffic Limit Consent of Independent Registered Public Accounting Firm To the Board of Directors Vycor Medical, Inc. |
|
| August 9, 2016 |
Vycor Medical Reports Financial Results for the three and six months ended June 30th, 2016 Blueprint Vycor Medical Reports Financial Results for the three and six months ended June 30th, 2016 BOCA RATON, FL (August 9, 2016) ? Vycor Medical, Inc. |
|
| August 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) |
|
| August 9, 2016 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2016 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charter) De |
|
| August 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Third Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK, PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numbe |
|
| August 9, 2016 |
VYCO / Vycor Medical, Inc. / ZACHARIOU PETER C - SCHEDULE 13D PZ Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Fourth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRRED STOCK PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numb |
|
| July 12, 2016 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13 D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Sixteenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Mana |
|
| April 28, 2016 |
Vycor Medical VYCOR-FORM 8K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2016 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) |
|
| April 28, 2016 |
Vycor Medical Reports Financial Results for the three months ended March 31st, 2016 EX-99.1 2 vycoq12016earningsrelease0.htm PRESS RELEASE Vycor Medical Reports Financial Results for the three months ended March 31st, 2016 BOCA RATON, FL (April 28, 2016) – Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the three months ended March 31, 2016. Vycor’s revenues for the quarter were $4 |
|
| April 28, 2016 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2016 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charter) T |
|
| April 7, 2016 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13 D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Fifteenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Mana |
|
| March 30, 2016 |
Untitled Document March 30, 2016 Dear Shareholder, 2015 saw the achievement of important strategic and operating milestones for both our businesses. |
|
| March 30, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2016 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) |
|
| March 30, 2016 |
Vycor Medical Reports Financial Results for the year ended December 31st, 2015 EX-99.1 2 vycoq42015earningsrelease0.htm PRESS RELEASE Vycor Medical Reports Financial Results for the year ended December 31st, 2015 BOCA RATON, FL (March 30, 2016) – Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2015. Operational Highlights NovaVision ● NovaVision lau |
|
| March 30, 2016 |
iUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K mainpages iUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-149782 VYCOR MEDICAL |
|
| February 17, 2016 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Third Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK, PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numbe |
|
| February 17, 2016 |
VYCO / Vycor Medical, Inc. / ZACHARIOU PETER C - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Third Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRRED STOCK PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numbe |
|
| January 8, 2016 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13 D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Fourteenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Man |
|
| November 13, 2015 |
Vycor Medical Reports Third Quarter 2015 Results vycoex991.htm Exhibit 99.1 Vycor Medical Reports Third Quarter 2015 Results BOCA RATON, FL (November 13, 2015) ? Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the third quarter and first nine months ended September 30, 2015. Operational Highlights NovaVision ? Novavision?s VRT has hitherto been, i |
|
| November 13, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2015 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Numbe |
|
| November 13, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charte |
|
| October 6, 2015 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13 D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Thirteenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Man |
|
| September 23, 2015 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-196334 Dated September 23, 2015 VYCOR MEDICAL, INC. 3,991,202 Shares of Common Stock Par Value $0.0001 Per Share This prospectus relates to the offering by the selling stockholders of VYCOR MEDICAL, INC. of up to 3,991,202 shares of our common stock underlying Series A and Series B warrants, par value $0.0001 per share. We will not receive any |
|
| September 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-196334 20-3369218 (State or Other Jurisdiction of (Commission File (I.R.S. Employer Incorporation) No.) Identification No.) 6401 Congress Ave |
|
| September 4, 2015 |
Vycor Medical WITHDRAWAL OF AMENDMENT TO A REGISTRATION STATEMENT Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 September 2, 2015 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vycor Medical, Inc.?Post-Effective Amendment No. 1 to Form S-1 (File No. 333-176713 filed on July 24, 2015)- Form AW - Application for Withdrawal of Amendment Ladies and Gentlemen: Pur |
|
| August 14, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition vyco8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2015 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identificat |
|
| August 14, 2015 |
Vycor Medical Releases Financial Results for the three and six months ended June 30st, 2015 vycoex991.htm Exhibit 99.1 Vycor Medical Releases Financial Results for the three and six months ended June 30st, 2015 BOCA RATON, FL (August 14, 2015) – Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the second quarter and first half ended June 30, 2015. Operational Highlights NovaVision ● Launche |
|
| August 14, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charter) De |
|
| August 11, 2015 |
VYCO / Vycor Medical, Inc. / ZACHARIOU PETER C - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Second Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRRED STOCK PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numb |
|
| August 11, 2015 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Second Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK, PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numb |
|
| August 7, 2015 |
Vycor Medical Inc. 6401 N Congress Avenue Suite 140 Boca Raton, FL 33487 August 5, 2015 Vycor Medical Inc. 6401 N Congress Avenue Suite 140 Boca Raton, FL 33487 August 5, 2015 By EDGAR Transmission U.S. Securities and Exchange Commission. 100 F Street N.E. Washington, D.C. 20549. Re: Vycor Medical, Inc. Amendment No. 1 to Post-Effective Amendment to Registration Statement on Form S-1 Filed July 24, 2015 File No. 333-196334 Ladies and Gentlemen: On behalf of Vycor Medical, Inc., Inc. |
|
| August 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amendment to Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-196334 20-3369218 (State or Other Jurisdiction of (Commission File (I.R.S. Employer Incorporation) No.) Identification No. |
|
| July 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-176713 20-3369218 (State or Other Jurisdiction of (Commission File (I.R.S. Employer Incorporation) No.) Identification No.) 6401 Congress Ave |
|
| July 24, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2015 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 6 |
|
| July 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Twelfth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manage |
|
| May 15, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charter) D |
|
| May 15, 2015 |
Vycor Medical CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2015 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 64 |
|
| May 15, 2015 |
Vycor Medical Releases Financial Results for the three months ended March 31st, 2015 Exhibit 99.1 Vycor Medical Releases Financial Results for the three months ended March 31st, 2015 BOCA RATON, FL (May 15, 2015) ? Vycor Medical, Inc. (?Vycor?) (OTCQB?VYCO), today announced financial results for the three months ended March 31, 2015. Company Highlights Vycor VBAS ? ViewSite Brain Access System (VBAS) has continued to gain traction through product approval in 9 new U.S. hospitals d |
|
| April 7, 2015 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Eleventh Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manag |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-149782 VYCOR |
|
| March 31, 2015 |
6401 Congress Avenue, Suite 140, Boca Raton, FL 33487, USA ☎ +1 561 558 2020 +1 561 620 2545 Exhibit 99.2 March 31, 2015 Dear Shareholder, 2014 was a busy year for Vycor, during which we welcomed a lot of new shareholders with our $5 million offering. As 2015 will also be an active year for our two businesses, we want to provide you with a clear understanding of what our strategic objectives are and how we are progressing to achieve those objectives. NOVAVISION Two weeks ago we announced |
|
| March 31, 2015 |
Vycor Medical CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) |
|
| March 31, 2015 |
EX-99.1 2 exhibit99-1.htm VYCOR MEDICAL, INC. PRESS RELEASE DATED MARCH 31, 2015 Exhibit 99.1 Vycor Medical Releases Financial Results for the twelve months ended December 31st, 2014 Vycor VBAS up 23% compared to 2013 Non-GAAP Net Loss reduced by 7% BOCA RATON, FL (March 31, 2015) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the year ended December 31, 2014. |
|
| February 19, 2015 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) First Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK, PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numbe |
|
| February 19, 2015 |
VYCO / Vycor Medical, Inc. / ZACHARIOU PETER C - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) First Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRRED STOCK PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Numbe |
|
| January 6, 2015 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Tenth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manageme |
|
| November 12, 2014 |
Exhibit 99.1 Vycor Medical Releases Financial Results for Third Quarter and First Nine Months of 2014 Vycor VBAS up 41% for first nine months over same period in 2013 Non-GAAP Net Operating Loss reduced by 12% BOCA RATON, FL (November 12, 2014) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the third quarter and first nine months of 2014. Company Highlights Vyc |
|
| November 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2014 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Numbe |
|
| November 12, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) T QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified |
|
| October 9, 2014 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Ninth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manageme |
|
| August 14, 2014 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Eighth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Managem |
|
| August 14, 2014 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK, PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Number) Fountainhead Ca |
|
| August 14, 2014 |
VYCO / Vycor Medical, Inc. / ZACHARIOU PETER C - FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) 7% SERIES D CONVERTIBLE REDEEMABLE PREFERRRED STOCK PAR VALUE $0.0001 (Title of Class of Securities) n/a (CUSIP Number) Peter C. Zachar |
|
| August 12, 2014 |
EX-99.1 2 d31598ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Reports 41% Year-to-Date Growth Revenue up 27% over first quarter 2013, with Vycor VBAS up 39% Revenue up 41% for first six months over same period in 2013 Non-GAAP Net Operating Loss reduced by 10% BOCA RATON, FL (August 12, 2014) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the second quarter and first s |
|
| August 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 12, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in i |
|
| August 8, 2014 |
Vycor Medical Boosts Shareholder Equity by $2.4 million EXHIBIT 99 EXHIBIT 99.1 Vycor Medical Boosts Shareholder Equity by $2.4 million BOCA RATON, FL (August 5, 2014) – Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB—VYCO), today announces that its largest shareholder, Fountainhead Capital Management Limited (“Fountainhead”), along with certain other related and non-related parties (together, the “Fountainhead Parties”), has agreed to exchange a |
|
| August 8, 2014 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| August 8, 2014 |
[FORM OF] SERIES B WARRANT TO PURCHASE COMMON STOCK VYCOR MEDICAL, INC. EX-10.4 6 d31591ex10-4.htm EX-10.4 Exhibit 10.4 Warrant to Purchase shares Of Common Stock (subject to adjustment) THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN EXEMPTION FROM SUCH REGISTRATION. [FORM OF] SER |
|
| August 8, 2014 |
SERIES A WARRANT TO PURCHASE COMMON STOCK VYCOR MEDICAL, INC. Warrant No EXHIBIT 10.3 Warrant to Purchase 572,613 shares Of Common Stock (subject to adjustment) THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN EXEMPTION FROM SUCH REGISTRATION. SERIES A WARRANT TO PURCHASE |
|
| August 8, 2014 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2014 |
Converted by EDGARwiz EXHIBIT 10.1 SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (this “Agreement”) is dated as of August 5, 2014, between Vycor Medical, Inc., a Delaware corporation (the “Company”), and Fountainhead Capital Management Limited (“Fountainhead”). WHEREAS, subject to the terms and conditions set forth in this Agreement, Fountainhead desires to exchange the total am |
|
| August 8, 2014 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| July 2, 2014 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Seventh Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manage |
|
| June 11, 2014 |
Dated June 10, 2014 VYCOR MEDICAL, INC. 6,767,254 Shares of Common Stock Par Value $0.0001 Per Share Filed Pursuant to Rule 424(b)(3) Registration No. 333-196334 Dated June 10, 2014 VYCOR MEDICAL, INC. 6,767,254 Shares of Common Stock Par Value $0.0001 Per Share This prospectus relates to the offering by the selling stockholders of VYCOR MEDICAL, INC. of up to 6,767,254 shares of our common stock, par value $0.0001 per share. We will not receive any proceeds from the sale of common stock. The sel |
|
| June 10, 2014 |
Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 June 10, 2014 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vycor Medical, Inc.—Amendment No. 1 to Form S-1 (File No. 333-176713)- Form AW - Application for Withdrawal of Amendment Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Se |
|
| June 10, 2014 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (First Amendment) VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-196334 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave |
|
| June 5, 2014 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (First Amendment) VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-176713 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave |
|
| May 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-176713 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave. Suite 140, Boca Raton, FL 33487 |
|
| May 19, 2014 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 19, 2014 |
Youâve Exceeded the SECâs Traffic Limit Exhibit 10 Exhibit 10.1 AMENDMENT AND WAIVER AGREEMENT THIS AMENDMENT AND WAIVER AGREEMENT (this “Agreement”), dated as of , 2014, is made and entered into by and among Vycor Medical, Inc., a Delaware corporation (the “Company”) and the signatories (the “Purchasers”) to that certain Securities Purchase Agreement, dated as of [DATE OF EACH AGREEMENT] (the “Purchase Agreement”), by and among the Com |
|
| May 19, 2014 |
Exhibit 99 Exhibit 99.1 Vycor Medical, Inc. Reports First Quarter 2014 Results Revenue up 55% over first quarter 2013 Vycor Medical Division Revenue Up 102% over same period 2013 Non-GAAP Net Operating Loss reduced by 29% BOCA RATON, FL (May 15, 2014) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the first quarter of 2014. Company Highlights - First Quarter · |
|
| May 19, 2014 |
AMENDMENT AND WAIVER AGREEMENT Exhibit 10 Exhibit 10.2 AMENDMENT AND WAIVER AGREEMENT THIS AMENDMENT AND WAIVER AGREEMENT (this “Agreement”), dated as of May 14, 2014, is made and entered into by and among Vycor Medical, Inc., a Delaware corporation (the “Company”) and the holders of certain Placement Agent Warrants (the “Warrants”) issued in connection with the Company’s private offering of securities during the period January |
|
| May 15, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) T QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in |
|
| April 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2014 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 30, 2014 |
Vycor Medical Completes Equity Offering EXHIBIT 99.1 Press Release dated April 28, 2014 Vycor Medical Completes Equity Offering BOCA RATON, FL (April 28, 2014) – Vycor Medical, Inc. (“Vycor” or the “Company”) (OTQCB—VYCO) on Friday April 25, 2014 completed the sale of $929,860 in Units comprising Common Stock and Warrants (the “Units”) to accredited investors (the “Investors”). The Units were issued pursuant to the terms of separate Sto |
|
| April 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-149782 VYCOR MEDICAL, INC. (Exa |
|
| April 7, 2014 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Sixth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manageme |
|
| March 31, 2014 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 333-149782 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 11-K [ ] Form 20-F [] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2013 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 10, 2014 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2014 |
CERTIFICATE OF CORRECTION STATE OF DELAWARE CERTIFICATE OF CORRECTION Converted by EDGARwiz EXHIBIT 3.1 CERTIFICATE OF CORRECTION STATE OF DELAWARE CERTIFICATE OF CORRECTION Vycor Medical, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware. DOES HEREBY CERTIFY: 1. The name of the corporation is Vycor Medical, Inc. 2. That a Certificate of Amendment of Certificate of Incorporation of Vycor Medical, I |
|
| February 4, 2014 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2014 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 7, 2014 |
Youâve Exceeded the SECâs Traffic Limit SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 2, 2014, between Vycor Medical, Inc. |
|
| January 7, 2014 |
Vycor Medical, Inc. PLACEMENT AGENT AGREEMENT Vycor Medical, Inc. PLACEMENT AGENT AGREEMENT Dated as of January 2, 2014 Gentlemen: Vycor Medical, Inc. (the “Company”) proposes to offer for sale (the “Offering”) in a private offering pursuant to Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”) (i) up to $3,000,000 of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock |
|
| January 7, 2014 |
Youâve Exceeded the SECâs Traffic Limit NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| January 7, 2014 |
Youâve Exceeded the SECâs Traffic Limit NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| January 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Fifth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manageme |
|
| January 7, 2014 |
Youâve Exceeded the SECâs Traffic Limit REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 2, 2014, between Vycor Medical, Inc. |
|
| January 7, 2014 |
Youâve Exceeded the SECâs Traffic Limit NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| January 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2014 Vycor Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34932 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 7, 2014 |
Vycor Medical Completes Initial Close of Equity Offering Vycor Medical Completes Initial Close of Equity Offering BOCA RATON, FL (January 3, 2014) – Vycor Medical, Inc. |
|
| November 25, 2013 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-176713 Dated November 6, 2013 VYCOR MEDICAL, INC. 615,597 Shares of Common Stock Par Value $0.0001 Per Share This prospectus relates to the offering by the selling stockholders of VYCOR MEDICAL, INC. of up to 615,597 shares of our common stock, par value $0.0001 per share. We will not receive any proceeds from the sale of common stock. The sell |
|
| November 15, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) T QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2013 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified |
|
| November 14, 2013 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 001-34932 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [XX] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2013 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| October 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post Effective Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-176713 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave |
|
| October 23, 2013 |
Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 October 23, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Kevin L. Vaughn, Accounting Branch Chief Re: Vycor Medical, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended December 31, 2012 File No. 1-34932 Filed on April 1, 2013 D |
|
| October 3, 2013 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Fourth Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Managem |
|
| August 14, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q HTML U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2013 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charte |
|
| July 1, 2013 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Third Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manageme |
|
| June 4, 2013 |
VYCO / Vycor Medical, Inc. / FOUNTAINHEAD CAPITAL MANAGEMENT LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Second Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Managem |
|
| May 15, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q HTML U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2013 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its chart |
|
| May 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) First Amendment INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) VYCOR MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 92921M203 (CUSIP Number) Fountainhead Capital Manageme |
|
| May 3, 2013 |
Vycor Announces Addition to Board of Directors Vycor Announces Addition to Board of Directors BOCA RATON, FL (May 3, 2013) – Vycor Medical, Inc. |
|
| May 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2013 Vycor Medical, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 333-149782 20-3369218 (State or Other Jurisdiction (Commission File Number) (IRS Employe |
|
| April 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-149782 VYCOR MEDI |
|
| January 17, 2013 | ||
| January 17, 2013 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2012 Vycor Medical, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 333-149782 20-3369218 (State or Other Jurisdiction (Commission File Number) (IRS Empl |
|
| December 21, 2012 |
Vycor Medical, Inc. Announces Management Change Converted by EDGARwiz EXHIBIT 99.1 Vycor Medical, Inc. Announces Management Change BOCA RATON, FL (December 21, 2012) – Vycor Medical, Inc. (“Vycor” or “Company”) (OTCBB: VYCO) announced today that Richard Denness will resign as the Company’s CEO effective December 31, 2012, and as a member of the Board of Directors effective immediately. Mr. Denness will remain as a consultant to the Company duri |
|
| December 19, 2012 |
SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: Preliminary Information Statement ξ Definitive Information Statement Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) VYCOR MEDICAL, INC. |
|
| December 5, 2012 |
Submission of Matters to a Vote of Security Holders - 8-K Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 5, 2012 |
Todays Alternative Energy Corp (Form: PRE 14C, Received: 04/05/2011 14:18:59) SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement Definitive Information Statement Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) VYCOR MEDICAL, INC. |
|
| November 14, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q HTML U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its c |
|
| September 20, 2012 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 20, 2012 |
Standard Letterhead Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 September 20, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Russell Mancuso, Branch Chief Re: Vycor Medical, Inc. (the “Company”) Post-Effective Amendment No. 1 to Form S-1 File No. 333-176713 Filed on September 6, |
|
| September 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-176713 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave |
|
| September 6, 2012 |
Standard Letterhead Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 September 4, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Russell Mancuso, Branch Chief Re: Vycor Medical, Inc. (the “Company”) Post-Effective Amendment No. 1 to Form S-1 File No. 333-176713 Filed on August 22, 20 |
|
| September 4, 2012 |
Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 September 4, 2012 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vycor Medical, Inc.—Post-Effective Amendment No. 1 to Form S-1 (File No. 333-149782)- Form AW - Application for Withdrawal of Amendment Ladies and Gentlemen: Pursuant to Rule 477 promu |
|
| August 22, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-176713 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave |
|
| August 22, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VYCOR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 333-176713 20-3369218 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 6401 Congress Ave |
|
| August 22, 2012 |
Converted by EDGARwiz Vycor Medical, Inc. 6401 Congress Ave. Suite 140 Boca Raton, FL 33487 August 22, 2012 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vycor Medical, Inc.—Post Effective Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-149782)-Form AW - Application for Withdrawal of Amendment Lad |
|
| August 14, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q HTML U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charte |
|
| July 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2012 Vycor Medical, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 333-149782 20-3369218 (State or Other Jurisdiction (Commission File Number) (IRS Employer |
|
| July 9, 2012 |
Vycor Medical, Inc. Announces Leadership Change, Appoints New Chief Executive Officer Vycor Medical, Inc. Announces Leadership Change, Appoints New Chief Executive Officer BOCA RATON, FL (July 2, 2012) – Vycor Medical, Inc. (“Vycor”) (OTCBB—VYCO) today announces that Richard P. Denness will be joining Vycor as its new Chief Executive Officer, replacing Ken Coviello on his departure following a transition period; Ken will retain a role with the company on a consultancy basis. Since |
|
| July 9, 2012 |
EMPLOYMENT AGREEMENT AGREEMENT (the “Agreement”) dated as of July 2, 2012, between VYCOR MEDICAL, INC. |
|
| May 15, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q HTML U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its chart |
|
| April 3, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 3, 2012 |
Converted by EDGARwiz Vycor Medical, Inc. Reports 2011 Results Revenue up 207% over 2010 including contribution from NovaVision Vycor Medical Division Revenue Up 78% over 2010 Vycor makes first Vycor shipment to China BOCA RATON, FL (April 3, 2012) – Vycor Medical, Inc. (“Vycor”) (OTCBB—VYCO) has reported 2011 revenue of $971,367, a 207% increase on the $316,450 for 2010. The Vycor Medical divisio |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K HTML UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-149782 VYCOR MEDICAL, INC. |
|
| March 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2012 Vycor Medical, Inc. (Exact name of registrant) Delaware 333-149782 20-3369218 (State of Incorporation) (Commission File Number) (I.R.S. Employer Ide |
|
| March 21, 2012 |
VYCOR MEDICAL, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS mainpages Exhibit 99.4 VYCOR MEDICAL, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On January 4, 2012, Vycor Medical, Inc.“(Vycor” or “the Company”) acquired all of the shares of Sight Science Limited (“Sight Science”) for a total of £384,768 ($597,660). In consideration of the Share Purchase Agreement and other Transaction agreements, the Company agreed to pay the Sight Sc |
|
| March 21, 2012 |
SIGHT SCIENCE LIMITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2011 Exhibit 99.2 SIGHT SCIENCE LIMITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2011 SIGHT SCIENCE LIMITED Balance Sheets September 30, 2011 June 30, 2011 (unaudited) ASSETS Current Assets Cash £ 16,346 £ 13,396 Accounts receivable, net 1,085 1,723 17,431 15,119 Fixed assets, net 3,841 4,344 TOTAL ASSETS £ 21,272 £ 19,463 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities A |
|
| March 21, 2012 |
SIGHT SCIENCE LIMITED FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2011 Exhibit 99.3 SIGHT SCIENCE LIMITED FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2011 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors Sight Science Limited Aberdeen, Scotland We have audited the accompanying balance sheet of Sight Science Limited as of June 30, 2011 and the related statement of operations, changes in stockholders’ deficit and cash flows for the year t |
|
| January 10, 2012 |
SHARE PURCHASE AGREEMENT between PROFESSOR ARASH SAHRAIE THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN NOVAVISION, INC. |
|
| January 10, 2012 |
Youâve Exceeded the SECâs Traffic Limit NON-COMPETE, NONDISCLOSURE, NON-COMPETE, NONDISCLOSURE, AND OWNERSHIP OF INTELLECTUAL PROPERTY AGREEMENT between A. |
|
| January 10, 2012 |
Vycor Medical, Inc. Acquires Sight Science Limited, a Highly Complementary business for NovaVision Vycor Medical, Inc Vycor Medical, Inc. Acquires Sight Science Limited, a Highly Complementary business for NovaVision BOCA RATON, FL (January 10, 2012) – Vycor Medical, Inc. (“Vycor”) (OTCBB—VYCO) today announced that its wholly owned subsidiary, NovaVision Inc. (“NovaVision”) has acquired all the shares of Sight Science Ltd. (“Sight Science”)(www.sightscience.com). As part of this acquisition, Pr |
|
| January 10, 2012 |
Youâve Exceeded the SECâs Traffic Limit OPTION AGREEMENT OPTION AGREEMENT between THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN and SIGHT SCIENCE LIMITED MBM COMMERCIAL LLP 5th Floor, 125 Princes Street, Edinburgh, EH2 4AD DX ED403 EDINBURGH TELEPHONE 0131 226 8200 FACSIMILE 0131-225 9212 Ref:VYC/0001/0001 Copyright © 2011, MBM COMMERCIAL LLP. |
|
| January 10, 2012 |
Patent Agreement between The University Court of the University of Aberdeen, a charity formed under the laws of Scotland, registered number SC013683 whose registered address is at the University Office, King’s College, Regent Walk, Aberdeen, AB24 3FX, a registered Scottish charity in terms of Section 13(2) of the Charities and Trustee Investment (Scotland) Act 2005, Charity Number SC013683, Charity Name “University of Aberdeen” (the “Assignor”); and Sight Science Limited, a company incorporated and registered in Scotland with company number SC311950 whose registered office is at William Guild Building, Kings College, University of Aberdeen, Regent Walk, Aberdeen, AB24 3FX, and its successors-in-interest (the “Assignee”). |
|
| January 10, 2012 |
Youâve Exceeded the SECâs Traffic Limit UNIVERSITY OF ABERDEEN UNIVERSITY OF ABERDEEN STAFF SECONDMENT AGREEMENT THIS AGREEMENT is made (together with the Schedule in two parts) (hereinafter collectively referred to as the "Agreement") between THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, a charity registered in Scotland, No SC013683, whose registered address is at University Office, King’s College, Regent Walk, Aberdeen AB24 3FX (hereinafter referred to as "the University") and NOVAVISION, INC. |
|
| January 10, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 9, 2011 |
HTML Filed Pursuant to Rule 424(b)(3) Registration No. 333-176713 Dated November 10, 2011 VYCOR MEDICAL, INC. 93,602,221 Shares of Common Stock Par Value $0.0001 Per Share This prospectus relates to the offering by the selling stockholders of VYCOR MEDICAL, INC. of up to 93,602,221 shares of our common stock, par value $0.0001 per share. We will not receive any proceeds from the sale of common sto |
|
| November 29, 2011 |
Vycor Medical Appoints Oscar Bronsther, M.D. to Board of Directors EXHIBIT 99.1 Vycor Medical Appoints Oscar Bronsther, M.D. to Board of Directors Boca Raton, FL- November 29, 2011-Vycor Medical, Inc. (OTCBB-VYCO) (?Vycor?) today announced that Oscar Bronsther, M.D., F.A.C.S was appointed to Vycor?s Board of Directors with immediate effect. Dr. Bronsther is currently Clinical Professor at George Washington University, Washington, DC. Dr. Bronsther has served as C |
|
| November 29, 2011 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 14, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q/A (Amendment #1) HTML U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q/A (Amendment #1) (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to VYCOR MEDICAL, INC. (Exact name of small business issuer as s |
